Literature DB >> 20116355

Chronic bilirubin encephalopathy: diagnosis and outcome.

Steven M Shapiro1.   

Abstract

Chronic bilirubin encephalopathy (kernicterus) can be diagnosed using semi-objective criteria based on history, physical and neurological examination and laboratory findings including auditory brainstem responses and magnetic resonance imaging. Classical kernicterus is a well-described clinical tetrad of (i) abnormal motor control, movements and muscle tone, (ii) an auditory processing disturbance with or without hearing loss, (iii) oculomotor impairments, especially impairment of upward vertical gaze, and (iv) dysplasia of the enamel of deciduous teeth. Subtle kernicterus or bilirubin-induced neurologic dysfunction (BIND) refers to individuals with subtle neurodevelopmental disabilities without classical findings of kernicterus that, after careful evaluation and consideration, appear to be due to bilirubin neurotoxicity. Kernicterus can be further classified as auditory predominant or motor predominant and characterized based on the severity of clinical sequelae. Proposed research definitions for kernicterus diagnosis in infants from 3 to 18 months are reviewed, as are treatments of auditory and motor deficits and other complications of bilirubin encephalopathy. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20116355     DOI: 10.1016/j.siny.2009.12.004

Source DB:  PubMed          Journal:  Semin Fetal Neonatal Med        ISSN: 1744-165X            Impact factor:   3.926


  42 in total

1.  Single dose of 50 mg/kg clofibrate in jaundice of healthy term neonates: randomised clinical trial of efficacy and safety.

Authors:  Razieh Fallah; Zia Islami; Saeid Reza Lotfi
Journal:  Indian J Pediatr       Date:  2011-07-22       Impact factor: 1.967

2.  Successful plasmapheresis for acute and severe unconjugated hyperbilirubinemia in a child with crigler najjar type I syndrome.

Authors:  Anne Laure Sellier; Philippe Labrune; Theresa Kwon; Alix Mollet Boudjemline; Georges Deschènes; Vincent Gajdos
Journal:  JIMD Rep       Date:  2011-09-06

3.  Reduced Myelination and Increased Glia Reactivity Resulting from Severe Neonatal Hyperbilirubinemia.

Authors:  Andreia Barateiro; Shujuan Chen; Mei-Fei Yueh; Adelaide Fernandes; Helena Sofia Domingues; João Relvas; Olivier Barbier; Nghia Nguyen; Robert H Tukey; Dora Brites
Journal:  Mol Pharmacol       Date:  2015-10-19       Impact factor: 4.436

4.  Reduced expression of UGT1A1 in intestines of humanized UGT1 mice via inactivation of NF-κB leads to hyperbilirubinemia.

Authors:  Ryoichi Fujiwara; Shujuan Chen; Michael Karin; Robert H Tukey
Journal:  Gastroenterology       Date:  2011-10-06       Impact factor: 22.682

5.  A decision-making tool for exchange transfusions in infants with severe hyperbilirubinemia in resource-limited settings.

Authors:  B O Olusanya; I F Iskander; T M Slusher; R P Wennberg
Journal:  J Perinatol       Date:  2016-03-03       Impact factor: 2.521

6.  Riluzole is a promising pharmacological inhibitor of bilirubin-induced excitotoxicity in the ventral cochlear nucleus.

Authors:  Guo-Ying Han; Chun-Yan Li; Hai-Bo Shi; Ji-Ping Wang; Kai-Ming Su; Xin-Lu Yin; Shan-Kai Yin
Journal:  CNS Neurosci Ther       Date:  2014-12-12       Impact factor: 5.243

7.  Relationship between behavioral hearing thresholds and estimated auditory steady-state response thresholds in children with a history of neonatal hyperbilirubinemia.

Authors:  Rasool Panahi; Zahra Jafari; Sara Hasani
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-06       Impact factor: 2.503

8.  Cross-talk between neurons and astrocytes in response to bilirubin: early beneficial effects.

Authors:  Ana Sofia Falcão; Rui F M Silva; Ana Rita Vaz; Sandra Leitão Silva; Adelaide Fernandes; Dora Brites
Journal:  Neurochem Res       Date:  2013-01-03       Impact factor: 3.996

9.  Cadmium and arsenic override NF-κB developmental regulation of the intestinal UGT1A1 gene and control of hyperbilirubinemia.

Authors:  Miao Liu; Shujuan Chen; Mei-Fei Yueh; Ryoichi Fujiwara; Camille Konopnicki; Haiping Hao; Robert H Tukey
Journal:  Biochem Pharmacol       Date:  2016-04-06       Impact factor: 5.858

10.  MRI and (1)H-MRS in adenosine kinase deficiency.

Authors:  C Staufner; H J Blom; C Dionisi-Vici; P Freisinger; N Makhseed; D Ballhausen; S Kölker; G F Hoffmann; I Harting
Journal:  Neuroradiology       Date:  2016-03-18       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.